Another decision from the strategic leaders of this company that may be innocent, but without amplifying explanation, smells very poor. First a price-depressed CR pre-lab results when those lab results are allegedly going to be positive for the company (and therefore the SP). Then a share-bonus for the leadership pre-EGM to rectify the ownership levels of the Directors after shareholders had their ownership diluted during a discounted CR, and now the Chairman dumping 15% of his ordinary shares at a depressed price when again, positive lab results are supposed to be imminent. This is either a case of the blind leading the blind, or...
